Statement of Comprehensive Income
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Paying users area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2012
- Price to Operating Profit (P/OP) since 2012
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get 1-month access to AbbVie Inc. for $24.99, or
get full access to the entire website for at least 3 months from $62.19.
This is a one-time payment. There is no automatic renewal.
We accept:
AbbVie Inc., consolidated statement of comprehensive income
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Comprehensive income item | Description | The company |
|---|---|---|
| Net earnings attributable to AbbVie Inc. | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | AbbVie Inc. net earnings attributable to AbbVie Inc. increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
| Comprehensive income attributable to AbbVie Inc. | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. | AbbVie Inc. comprehensive income attributable to AbbVie Inc. increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |